← Eichor
Condition: Atypical Neurofibroma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Atypical Neurofibroma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Phase 1/Phase 2 · 2 location(s) · AeRang Kim · NCT06735820Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06222203Neurofibromatosis Type 1 Tumor Early Detection Study
Phase N/A · 1 location(s) · David Miller · NCT06515860Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT04750928
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.